Millennium Management
CTMX icon

Millennium Management’s CytomX Therapeutics CTMX Stock Holding History

Millennium Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$387K – 6603
2021
Q1 		$387K Buy
+50,000
New +$396K ﹤0.01% 5033

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management's CTMX Position: Q1 2026 in Review

Millennium Management increased its CytomX Therapeutics (CTMX) stake by 1,164% in Q1 2026, buying an estimated $17.1M and bringing the position to 3,660,190 shares worth $17.2M. The position accounts for 0.01% of the portfolio, ranked #1673.

Millennium Management first reported a position in CTMX in Q2 2016 and has held it in 39 quarters since. The position peaked at $17.7M in Q4 2017. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Millennium Management held 3,660,190 shares of CytomX Therapeutics worth $17.2M as of Q1 2026.
  • Millennium Management bought 3,370,537 CytomX Therapeutics shares in Q1 2026, an estimated $17.1M.
  • CytomX Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1673 holding.
  • Millennium Management first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 39 quarters since.
  • Millennium Management's CytomX Therapeutics position peaked at $17.7M in Q4 2017.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.